The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model
Open accessAbstract
The neuroendocrine and behavioral effects of chronic paroxetine treatment were investigated in two rat lines selectively bred for high anxiety-related behavior (HAB) or low anxiety-related behavior (LAB) emotionality. In addition to a characteristic behavioral phenotype with markedly passive stress-coping strategies, HAB rats show a hypothalamic vasopressinergic hyperdrive that is causally related to hypothalamic-pituitary-adrenocortical dysregulation as demonstrated in the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test. A total of 8 weeks of chronic paroxetine treatment induced a more active coping strategy in the forced swim test in HAB rats only. In contrast, paroxetine-treated LAB rats did not change their swimming behavior. To investigate the neuroendocrine alterations linked to these behavioral changes, a combined DEX/CRH test was performed. In HAB rats, the paroxetine-induced behavioral changes towards more active coping strategies were accompanied by a normalization of the CRH-stimulated increase in corticotropin (ACTH) and corticosterone secretion. Concomitantly, the hypothalamic vasopressinergic hyperdrive was found to be reduced in HAB but not LAB rats, as indicated by a decrease in vasopressin mRNA expression, whereas vasopressin 1a receptor binding was unaffected. These findings provide the first evidence that the vasopressinergic system is likely to be critically involved in the behavioral and neuroendocrine effects of antidepressant drugs. This novel mechanism of action of paroxetine on vasopressin gene regulation renders vasopressinergic neuronal circuits a promising target for the development of more causal antidepressant treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · cited 1×
“It is well established that AVP potently synergizes with CRH to stimulate pituitary ACTH secretion (von Bardeleben and Holsboer, 1989; Gillies et al, 1982).”
BackgroundVasopressinergic control of pituitary adrenocorticotropin secretion comes of age
Antoni, F. A. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1004 · Cited by 636
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · cited 1×
“Most recently, administration of a nonpeptide AVP vasopressin 1b (V1b) receptor antagonist was shown to display anxiolytic and antidepressant-like effects in rodents (Griebel et al, 2002).”
BackgroundPurba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Vasopressin and oxytocin receptors in the central nervous system
Tribollet, E., & Barberis, C. (1996) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v10.i1.60 · Cited by 399 · cited 2×
“The V1a receptor, which is highly expressed in the rat lateral septum, thalamic nuclei, and the amygdalostriatal transition area (Barberis and Tribollet, 1996), is well known to play a role in a variety of behavioral effects such as the modulation of emotionality and stress coping (Landgraf et al, 1998).”
BackgroundZobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354
Self-citationLandgraf, R., Gerstberger, R., Montkowski, A., Probst, J., Wotjak, C., Holsboer, F., & Engelmann, M. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-06-04250.1995 · Cited by 341
Self-citationPlasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.656 · Cited by 278
Neuropeptides and the evolution of social behavior
Insel, T. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00146-x · Cited by 264 · cited 2×
“AVP has been shown to exert both behavioral effects such as, for example, increased anxiety following intracerebroventricular administration, and to increase CRH-induced corticotropin (ACTH) secretion from pituitary corticotrope cells (Antoni, 1993; Landgraf et al, 1998; Bhattacharya et al, 1998; Insel and Young, 2000…”
BackgroundInfluential
Cited by
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Landgraf, R., & Neumann, I. D. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.05.001 · Cited by 1,059
Self-citationNeumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Self-citationThe Effects of Psychological Stress on Depression
Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831150507 · Cited by 589
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The stress system in depression and neurodegeneration: Focus on the human hypothalamus
Bao, A.-M., Meynen, G., & Swaab, D. F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.04.005 · Cited by 548
Stress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473
“These animals are characterized by an overexpression of central AVP (Landgraf 2006), and treatment with an antidepressant led to a gradual reduction of AVP hypersecretion, reflected by decreased stress-hormone response to dexamethasone/CRH-challenges (Keck et al. 2003).”
BackgroundSelf-citationFactors influencing behavior in the forced swim test
Bogdanova, O. V., Kanekar, S., D'Anci, K. E., & Renshaw, P. F. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.05.012 · Cited by 464
Engelmann, M., Landgraf, R., & Wotjak, C. T. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.09.001 · Cited by 450
Self-citationMikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Holmes, A., Heilig, M., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 403
Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341
Self-citationAlonso, R., Griebel, G., Pavone, G., Stemmelin, J., Le Fur, G., & Soubrié, P. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001464 · Cited by 319
The role of substance P in stress and anxiety responses
Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 306
High vs Low Anxiety-Related Behavior Rats: An Animal Model of Extremes in Trait Anxiety
Landgraf, R., & Wigger, A. (2002) · Behavior Genetics · doi:10.1023/a:1020258104318 · Cited by 274
Self-citationEffects of early life stress on adult male aggression and hypothalamic vasopressin and serotonin.
Veenema, A. H., Blume, A., Niederle, D., Buwalda, B., & Neumann, I. D. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05045.x · Cited by 271
The combined dexamethasone/CRH test as a potential surrogate marker in depression
Ising, M., Künzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 271
Self-citationJaglin, M., Rhimi, M., Philippe, C., Pons, N., Bruneau, A., Goustard, B., Daugé, V., Maguin, E., Naudon, L., & Rabot, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00216 · Cited by 269
Veenema, A. H. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.03.003 · Cited by 267
Wigger, A., Sánchez, M. M., Mathys, K. C., Ebner, K., Frank, E., Liu, D., Kresse, A., Neumann, I. D., Holsboer, F., Plotsky, P. M., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300290 · Cited by 263
Self-citationChronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats
Slattery, D. A., & Neumann, I. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.038 · Cited by 195
Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner
Schmidtner, A. K., Slattery, D. A., Gläsner, J., Hiergeist, A., Gryksa, K., Malik, V. A., Hellmann-Regen, J., Heuser, I., Baghai, T. C., Gessner, A., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0556-9 · Cited by 153
Beiderbeck, D. I., Neumann, I. D., & Veenema, A. H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05974.x · Cited by 142
Born to be anxious: neuroendocrine and genetic correlates of trait anxiety in HAB rats
Landgraf, R., & Wigger, A. (2003) · Stress · doi:10.1080/1025389031000104193 · Cited by 122
Self-citationMeynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., & Hoogendijk, W. J. G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.010 · Cited by 108
“Moreover, Keck et al. showed in an animal model of depression that a reduction of the hypothalamic vasopressinergic hyperdrive following paroxetine treatment contributes to clinically relevant behavioral and neuroendocrine effects (Keck et al., 2003).”
BackgroundInfluentialAnxiety and Hippocampus Volume in the Rat
Kalisch, R., Schubert, M., Jacob, W., Keßler, M. S., Hemauer, R., Wigger, A., Landgraf, R., & Auer, D. P. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300910 · Cited by 96
Self-citationTransient inactivation of the infralimbic cortex induces antidepressant-like effects in the rat
Slattery, D. A., Neumann, I. D., & Cryan, J. F. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110368873 · Cited by 77
“Previously, chronic treatment with paroxetine over 8 weeks (Keck et al., 2003) or direct infusion of an AVP-receptor antagonist into the PVN (Wigger et al., 2004) have been shown to decrease the high depression-related behaviour in HAB rats.”
BackgroundResultInteraction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour
Beurel, E., & Nemeroff, C. B. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_306 · Cited by 64
“CNS AVP circuits also promote depressive behavior in rats, and these effects are blocked by the administration of antidepressants (Keck et al., 2003).”
BackgroundBrain vasopressin signaling modulates aspects of maternal behavior in lactating rats
Bayerl, D. S., & Bosch, O. J. (2019) · Genes, Brain and Behavior · doi:10.1111/gbb.12517 · Cited by 46
Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist
Fabio, K. M., Guillon, C. D., Lu, S.-F., Heindel, N. D., Brownstein, M. J., Lacey, C. J., Garippa, C., & Simon, N. G. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23495 · Cited by 34
Metadata
- Authors
- Keck, M. E., Welt, T., Müller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., & Landgraf, R.
- Venue
- Neuropsychopharmacology
- Published
- 2002-07-25
- Volume
- 28
- Issue
- 2
- Pages
- 235-243
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2048146758
- Cited by
- 168
- References
- 14
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.